



Healthcare
Improvement
Scotland

SMC
Advice on new
medicines

www.scottishmedicines.org.uk

Product update
SMC2756

sumatriptan 85mg / naproxen 457mg (Suvexx®)

Orion Pharma UK Ltd

09 May 2025

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

sumatriptan 85mg / naproxen 457mg (Suvexx®) is not recommended for use within NHSScotland.

Indication under review: the acute treatment of the headache phase of migraine attacks with or without aura in adults where treatment with a mono-entity product has been insufficient.

Suvexx® offers a combination tablet of sumatriptan and naproxen. It is available at a considerable cost premium to sumatriptan 100mg and naproxen 500mg tablets taken separately.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 27 February 2025.

Chair
Scottish Medicines Consortium

Published 09 June 2025